Stoke Therapeutics (STOK) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zymeworks (ZYME) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 8.8% versus a loss of 8.6%. Over five years, ZYME leads with a +34.1% price change compared with +6.8% for STOK. Zymeworks is the larger company by market cap ($1.81 billion vs $1.75 billion), about 1.0 times the size, while Stoke Therapeutics is growing revenue faster (+404.5% vs +38.9%).
Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -76.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | STOK | ZYME |
|---|---|---|
| Share price | $26.81 | $26.14 |
| Market cap | $1.75B | $1.81B |
| 1-day change | -0.45% | -2.68% |
| YTD return | -15.53% | -0.72% |
| 1-year return | -8.62% | +8.83% |
| 5-year return | +6.77% | +34.05% |
| P/E ratio (TTM) | — | 49.32 |
| Forward P/E | — | 54.95 |
| EPS (TTM) | $-3.81 | $0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $184.42M | $105.97M |
| Revenue growth (YoY) | +404.50% | +38.87% |
| Net income (latest FY) | $-6.88M | $-81.13M |
| Operating margin | -11.16% | -87.34% |
| Net margin | -3.73% | -76.56% |
| 52-week high | $40.22 | $31.97 |
| 52-week low | $22.05 | $21.52 |
| Distance from 52-week high | -33.34% | -18.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +73.00% | +65.61% |
| Average volume | 1.02M | 1.09M |
| Shares outstanding | 65.41M | 68.70M |
| Employees | 170 | 279 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed STOK by 17.4 percentage points over the past year.
- Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -76.6 cents for Zymeworks.
- Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs +38.87%).
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees
STOK vs ZYME FAQ
Which is bigger, Stoke Therapeutics or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.81B compared with $1.75B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, STOK or ZYME?
ZYME returned +8.83% over the past 12 months, compared with -8.62% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Stoke Therapeutics and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.